论文信息 - AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations - 字舞流文

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou | V. Miller | Siraj M. Ali | He-long Zhang | Baolan Li | Chengping Hu | R. Guo | Z. Jie | N. Yang | Xiaorong Dong | Haihua Yang | J. Duan | Jie Hu | Gong-yan Chen | Shun Lu | Chunhong Hu | Liyan Jiang | Jianying Zhou | Longzhen Zhang | Yuping Sun | Jifeng Feng | Zhuang Yu | J. Xiong | Zhehai Wang | Qiming Wang | Ziping Wang | Yuan Chen | Jianhua Chen | Yan-ping Hu | Junguo Lu | Xingxiang Xu | Chunling Liu | Xianwei Ye | Meili Sun | Yinghua Ji | Jianhua Shi | J. Cui | Jian Fang | Xin-min Yu | Weidong Li | Zhong Lin | D. Lv | H. Jian | Guojun Zhang | R. Ma | Zhihong Zhang | Yu Yao | Weng Jie | Juan Li | Shaoshui Chen | Lin Ma | Xiaohong Wu | Zhi-Li Xu | You Lu | Wancheng Tong | Chang-hai Sun | H. Wei | Chuan-yin Li | Qiong Wu | J. Fang | S. Lu | X. Dong | Xinmin Yu | Gongyan Chen | Xiaorong Dong